Antiinflammatory effects of JAKi in patients with VEXAS syndrome. (A) Overall clinical response rates of patients treated with JAKi during 1, 3, or 6 months; results are presented for the whole cohort (left), for patients receiving other JAKi than ruxolitinib (middle), or for patients receiving ruxolitinib (right). (B) Overall biological response rates of patients treated with JAKi during 1, 3, or 6 months; results are presented for the whole cohort (left), for patients receiving other JAKi than ruxolitinib (middle), or for patients receiving ruxolitinib (right).